(Q47352521)

14 January 2018

title

Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia (English)

1 reference

14 January 2018

0 references

2

1 reference

14 January 2018

author name string

Mochtar CA

1

1 reference

14 January 2018

van Riemsdijk MM

3

1 reference

14 January 2018

Barnett GS

4

1 reference

14 January 2018

Laguna MP

5

1 reference

14 January 2018

Debruyne FM

6

1 reference

14 January 2018

de la Rosette JJ

7

1 reference

14 January 2018

language of work or name

English

0 references

publication date

1 December 2003

1 reference

14 January 2018

published in

European Urology

1 reference

14 January 2018

volume

44

1 reference

14 January 2018

issue

6

1 reference

14 January 2018

page(s)

695-700

1 reference

14 January 2018

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

Prediction of prostate volume based on total and free serum prostate-specific antigen: is it reliable?

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

Prostate-specific antigen levels in 1695 men without evidence of prostate cancer. Findings of the American Cancer Society National Prostate Cancer Detection Project

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

Relationship between prostate specific antigen, prostate volume and age in the benign prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

Prostate specific antigen in a community-based sample of men without prostate cancer: correlations with prostate volume, age, body mass index, and symptoms of prostatism.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

Relationship among age, prostate-specific antigen, and prostate volume in men with lower urinary tract symptoms (LUTS) and in different groups of men with and without benign and malignant prostate diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

Long-Term Risk Of Re-Treatment Of Patients Using α-Blockers For Lower Urinary Tract Symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

Clinical characteristics of alpha-blocker responders in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

Natural history of prostatism: risk factors for acute urinary retention

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

Interexaminer reliability and validity of a three-dimensional model to assess prostate volume by digital rectal examination

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

Determination of prostate volume with transrectal US for cancer screening. Part II. Accuracy of in vitro and in vivo techniques

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

The role of transabdominal ultrasound in the preoperative evaluation of patients with benign prostatic hypertrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

Medical therapy for benign prostatic hyperplasia: a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900384-1

7 January 2021

10.1016/S0302-2838(03)00384-1

Identifiers

DOI

1 reference

14 January 2018

PubMed ID

14644122

1 reference

14 January 2018